Beta Bionics (BBNX) Resumen de Acciones
Beta Bionics, Inc. es una empresa de dispositivos médicos en fase comercial que se dedica al diseño, desarrollo y comercialización de soluciones para mejorar la salud y la calidad de vida de las personas diabéticas que necesitan insulina. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 1/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
BBNX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Beta Bionics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$16.86 |
| Máximo en las últimas 52 semanas | US$32.71 |
| Mínimo de 52 semanas | US$8.80 |
| Beta | 0 |
| Cambio en 1 mes | 17.25% |
| Variación en 3 meses | 38.42% |
| Cambio de 1 año | 33.18% |
| Variación en 3 años | n/a |
| Variación en 5 años | n/a |
| Variación desde la OPV | -28.65% |
Noticias y actualizaciones recientes
BBNX: Regulatory Recalls And Legal Probe Will Drive A More Cautious Outlook
Analysts have reset the fair value estimate for Beta Bionics to $13.00 from $25.00, reflecting a series of reduced price targets across the Street that weigh a lower assumed future P/E multiple alongside updated views on revenue growth and profit margins, even as some highlight supportive FDA feedback and an earlier expected Mint launch timeline. Analyst Commentary Recent Street research on Beta Bionics points to a mixed backdrop, with a cluster of reduced price targets alongside some more constructive commentary tied to regulatory progress and the Mint launch timeline.Beta Bionics: Some Stabilization In Sight
Summary Beta Bionics´ shares rebounded 60% after a modest guidance hike and improved gross margin, following a severe early-year selloff. Beta Bionics now guides for $131–$136 million in 2024 sales and 57.5–59.5% gross margins, reflecting incremental operational progress. Despite a $240 million net cash position, Beta Bionics trades at just over 3x sales, with ongoing operating losses and intense competition. I maintain a neutral stance, monitoring sales and margin momentum as Beta Bionics addresses FDA concerns and eyes the Type 2 diabetes market. Read the full article on Seeking AlphaRecent updates
BBNX: Regulatory Recalls And Legal Probe Will Drive A More Cautious Outlook
Analysts have reset the fair value estimate for Beta Bionics to $13.00 from $25.00, reflecting a series of reduced price targets across the Street that weigh a lower assumed future P/E multiple alongside updated views on revenue growth and profit margins, even as some highlight supportive FDA feedback and an earlier expected Mint launch timeline. Analyst Commentary Recent Street research on Beta Bionics points to a mixed backdrop, with a cluster of reduced price targets alongside some more constructive commentary tied to regulatory progress and the Mint launch timeline.Beta Bionics: Some Stabilization In Sight
Summary Beta Bionics´ shares rebounded 60% after a modest guidance hike and improved gross margin, following a severe early-year selloff. Beta Bionics now guides for $131–$136 million in 2024 sales and 57.5–59.5% gross margins, reflecting incremental operational progress. Despite a $240 million net cash position, Beta Bionics trades at just over 3x sales, with ongoing operating losses and intense competition. I maintain a neutral stance, monitoring sales and margin momentum as Beta Bionics addresses FDA concerns and eyes the Type 2 diabetes market. Read the full article on Seeking Alpha
BBNX: Mint Launch Timeline And Regulatory Progress Will Drive Future Upside
The analyst price target for Beta Bionics has been revised lower by approximately $10.81. This change reflects a series of reduced targets across several firms as analysts incorporate updated medtech sector valuations and refreshed expectations for the company’s growth, profitability, and future P/E assumptions.Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Beta Bionics, Inc.'s (NASDAQ:BBNX) Popularity With Investors Under Threat As Stock Sinks 58%
The Beta Bionics, Inc. ( NASDAQ:BBNX ) share price has fared very poorly over the last month, falling by a substantial...Pharmacy-Driven Diabetes Technology Adoption Will Support A Stronger Long-Term Outlook
Catalysts About Beta Bionics Beta Bionics develops automated insulin delivery systems aimed at simplifying diabetes management for people using insulin pumps. What are the underlying business or industry changes driving this perspective?We're Hopeful That Beta Bionics (NASDAQ:BBNX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Beta Bionics, Inc. (NASDAQ:BBNX) Looks Just Right With A 35% Price Jump
Despite an already strong run, Beta Bionics, Inc. ( NASDAQ:BBNX ) shares have been powering on, with a gain of 35% in...Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Beta Bionics: Slowing Down Or Being Conservative?
Summary Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure. With substantial net cash holdings, the stock remains interesting if the guidance is conservative, offering potential upside given the current low valuation. Read the full article on Seeking AlphaBeta Bionics: A Sugar Rush For This IPO
Summary Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company’s iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to expand to Type 2, doubling the market potential. Despite impressive revenue growth, Beta Bionics faces substantial operating losses, but it has a solid cash position to fund these losses for years. While the growth is compelling, risks include competition, reliance on partners, and the single-product nature, making me cautious about initiating a position now. Read the full article on Seeking AlphaRentabilidad de los accionistas
| BBNX | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 4.2% | -2.7% | 0.8% |
| 1Y | 33.2% | -20.6% | 20.5% |
Rentabilidad vs. Industria: BBNX superó a la industria US Medical Equipment, que obtuvo un rendimiento del -20.6% el año pasado.
Rentabilidad vs. Mercado: BBNX superó al mercado US, que obtuvo un rendimiento del 20.5% el año pasado.
Volatilidad de los precios
| BBNX volatility | |
|---|---|
| BBNX Average Weekly Movement | 9.9% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: BBNX no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BBNX (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 422 | Sean Saint | www.betabionics.com |
Beta Bionics, Inc. es una empresa de dispositivos médicos en fase comercial que se dedica al diseño, desarrollo y comercialización de soluciones para mejorar la salud y la calidad de vida de las personas diabéticas que necesitan insulina. Ofrece iLet Bionic Pancreas, un dispositivo de administración de insulina para el tratamiento de la diabetes de tipo 1 en adultos y niños mayores de seis años. La empresa también está desarrollando Patch Pump, una bomba de insulina diseñada para adherirse directamente a la piel y administrar insulina sin necesidad de tubos; Bihormonal iLet, que combina la administración automatizada de insulina y glucagón; e iLet para tratar a personas con diabetes de tipo 2 insulinodependientes.
Resumen de fundamentos de Beta Bionics, Inc.
| Estadísticas fundamentales de BBNX | |
|---|---|
| Capitalización bursátil | US$751.31m |
| Beneficios(TTM) | -US$66.44m |
| Ingresos (TTM) | US$110.24m |
¿Está BBNX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BBNX | |
|---|---|
| Ingresos | US$110.24m |
| Coste de los ingresos | US$47.24m |
| Beneficio bruto | US$63.00m |
| Otros gastos | US$129.44m |
| Beneficios | -US$66.44m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 29, 2026
| Beneficios por acción (BPA) | -1.49 |
| Margen bruto | 57.15% |
| Margen de beneficio neto | -60.27% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado BBNX a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/15 12:20 |
| Precio de las acciones al final del día | 2026/07/15 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Beta Bionics, Inc. está cubierta por 14 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | BofA Global Research |
| David Roman | Goldman Sachs |